Hypertension
Conditions
Interventions
Group 5:(Total Cholesterol concentration of participants: 6.1mmol/L). Amlodipine 2.5mg and compound amiloride half of a tablet.
Group 6:(Total Cholesterol concentration of participants 6.1mmol/L). Amlodipine 2.5mg and telmisartan 40mg.
Group 3:(Total Cholesterol concentration of participants: 4.0-6.1mmol/L). Amlodipine 2.5mg, telmisartan 40mg and simvastatin 10mg.
Group 4:(Total Cholesterol concentration of participants: 4.0-6.1mmol/L). Amlodipine 2.5mg and telmisartan 40mg, regular remedy of serum lipid decided by the doctors.
Group 2:(Total Cholesterol concentration of participants 4.0-6.1mmol/L). Amlodipine 2.5mg and compound amiloride half of a tabella and regular remedy of serum lipid decided by the doctors.
Group 1:(Total Cholesterol concentration of participants: 4.0-6.1mmol/L). Amlodipine 2.5mg, compound amiloride 2.5mg and simvastatin 10mg
Group A:(Includes group 1, group 2, and group 5). Amlodipine 2.5mg, compound amiloride half of a tablet.
Group B:(Includes group 3, group 4 and group 6). Amlodipine 2.5mg, telmisartan 40mg.
Sponsors
Fu Wai Hospital for Cardiovascular Disease
Eligibility
Sex/Gender
All
Age
50 Years to 79 Years
Inclusion criteria
Inclusion criteria: 1. primary hypertension; 2. age 50~79 year; 3. with one or more risk factor on cardiovascular disease; 4. able to sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. secondary hypertension; 2. acute cardiovascular events happened in recent 3 months; 3. complicated with severe cardiomyopathy, rheumatic valvular disease or congenital heart disease; 4. complicated with unstable angina; 5. complicated with severe hepatic or renal disease(ALT elevated more than 2 times or creatinine >2.5mg/dl); 6. complicated with malignant tumor; 7. complicated with gout; 8. with intake of contraceptive medicine or possibility of pregnancy; 9. Allergic to certain medicine; 10. Contraindications of certain medicine; 11. The patients are participating in other clinical trials; 12. difficult to follow up or poor compliance; 13. improper to participate in the trial judged by the doctor in charge.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence rate of compound cardiovascular event; | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of life style;Change of blood pressure;blood pressure control rate;Change of eye fundus;Quality of Life;Change of MMSE;Change of the knowlege of hypertention;Incidence of stroke;Incidence of diabetes;Incidence of atrial fibrillation; | — |
Countries
China
Contacts
Public ContactWen Wang
Outcome results
None listed